ESTRO 2025 - Abstract Book

S1890

Clinical - Urology

ESTRO 2025

527

Digital Poster SPANISH CLINICAL MANAGEMENT IN HIGH-RISK PROSTATE CANCER: RESULTS FROM A NATIONAL SURVEY Victor Duque-Santana 1,2 , Marian Gomez Aparicio 3 , Abrahams Ocanto 4 , Elias Gomis 5 , Fernando Lopez-Campos 6 , on behalf of URONCOR investigators duque 7 1 Radiation Oncology, H.U. Quironsalud, Madrid, Spain. 2 Department of Medicine, Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Madrid, Spain. 3 Radiation Oncology, H.U. Toledo, Toledo, Spain. 4 Radiation Oncology, H.U. San Francisco de Asis GenesiCare, Madrid, Spain. 5 Radiation Oncology, Hospital Clinic, Barcelona, Spain. 6 Radiation Oncology, H.U. Ramon y Cajal, Madrid, Spain. 7 Radiation Oncology, URONCOR, Madrid, Spain Purpose/Objective: The management of high-risk(HR) prostate cancer represents a challenge for radiation oncologists. This survey investigates the pattern of care in management of HR-prostate cancer across Spanish institutions. Material/Methods: We conducted a survey among URONCOR members from March to May, 2024. This survey was structured in 5 sections: diagnosis, radiotherapy(RT), hormonal treatment(HT), follow-up and future perspectives. Results: A total of 73 responses from 71 different hospitals were received. Participants have a median professional experienced of 11 years, working most of them(84.9%) in public university hospitals. 97.3% have multidisciplinary tumor board and treat a median of 50(0-200) HR-prostate cancer patients per year/department. 44.63% of centers use Choline-PET and 28.4% PSMA-PET at diagnosis with 26 different fractionation schedules, the most common is moderate hypofractionation(52.7%): 70Gy in 28 fractions, followed by 37.5Gy in 15 fractions + 15Gy brachytherapy boost(30.4%). 56.8% of the institutions perform whole-pelvic irradiation in N0 patients, with 50.4Gy in 28 fractions(40.48%) being the most common scheme. 56.8% prescribe an LHRH-agonist and 74.6% for 24 months. 75.7% prescribe abiraterone in very high- risk patients. 72.60% use the PHOENIX-criteria to define a recurrence. 49.31% perform PSMA-PET and 47.95% Choline-PET as imaging for recurrence. After local relapse, 73.97% apply a re-irradiation technique with 11 different schedules(32.35%), with HDR-brachytherapy: 13.5Gy x 2 being the most used(56.16%). 83.8% consider that they achieved good results in HR-prostate cancer.